Compositions, Methods And Systems For Aerosol Drug Delivery
Patent No. EP4175620 (titled "Compositions, Methods And Systems For Aerosol Drug Delivery") was filed by Astrazeneca Pharmaceuticals LP on Jul 8, 2022. The application was issued on Apr 10, 2024.
Patent Summary
Targeted drug delivery system for respiratory therapy that delivers active agents to the respiratory tract through a metered dose inhaler. The system comprises a propellant of pharmaceutical grade HFO-1234ze(E) and a combination of glycopyrrolate, formoterol, and budesonide particles. The propellant is formulated with perforated microstructured phospholipid particles, which provide mechanical stability and prevent aggregation. The combination delivers precise, controlled doses of these active agents through the inhaler's actuator mechanism, maintaining consistent delivery performance even in simulated storage conditions.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4175620
- Application Number
- EP22751897A
- Filing Date
- Jul 8, 2022
- Status
- Granted And Under Opposition
- Mar 8, 2024
- Publication Date
- Apr 10, 2024
- External Links
- Slate, Register , Google Patents